Veradermics/$MANE
1D1W1MYTD1Y5YMAX
Capital at risk
About Veradermics
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
- Ticker
- $MANE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 37
- Headquarters
- New Haven, United States
- Website
- www.veradermics.com
Veradermics Metrics
BasicAdvanced
$4.8B
-
-$6.44
-
-
Price and volume
Market cap
$4.8B
52-week high
$131.24
52-week low
$32.00
Average daily volume
700K
Financial strength
Current ratio
70.527
Quick ratio
70.248
Long term debt to equity
0.001
Total debt to equity
0.001
Profitability
Management effectiveness
Valuation
Price to book
5.91
Price to tangible book (TTM)
5.91
Price to free cash flow (TTM)
-23.762
Free cash flow yield (TTM)
-4.21%
Free cash flow per share (TTM)
-4.84
Growth
What the Analysts think about Veradermics
Analyst ratings (Buy, Hold, Sell) for Veradermics stock.
Analyst projections of the future price of Veradermics stock.
Bulls say / Bears say
Veradermics held a cash position of $819.9 million at June 30, 2026, which management expects will fund operations into 2030, providing runway beyond key Phase 3 readouts and potential NDA submission (Reuters)
The company is advancing its lead program VDPHL01 with topline data from the confirmatory Phase 3 Study 304 in male pattern hair loss expected in the second half of 2026, marking critical progress in its registrational pathway (Reuters)
A May 2026 follow-on public offering and concurrent private placement generated approximately $472 million in gross proceeds, strengthening the balance sheet ahead of multiple anticipated Phase 3 readouts (FT)
Net loss widened to $23.5 million in the second quarter ended June 30, 2026, underscoring ongoing unprofitable operations amid clinical development acceleration (Reuters)
Research and development expenses rose materially in Q2 2026 due to increased clinical activity for VDPHL01, while G&A costs climbed from commercial readiness and higher personnel headcount, pressuring cash burn (Reuters)
Veradermics reported a fourth-quarter net loss of $21.8 million for the period ended December 31, 2025, highlighting persistent historical losses prior to potential product approval (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Veradermics Financial Performance
Revenues and expenses
Veradermics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Veradermics News
AllArticlesVideos
Veradermics to Present at Upcoming September Investor Conferences
Business Wire4 weeks ago
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Business Wire2 months ago
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Business Wire2 months ago
Funds containing Veradermics
AllEURGBPUSD
Fund name | Fund size | $MANE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.08% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.